江龙光
日期:2023-09-15 阅读次数: 作者: 来源:

https://cms.fzu.edu.cn/_vsl/D75B40EAC96391C3665151F7DA546FC1/810FEF56/BFE94?e=.jpg

姓名

Name

江龙光

Longguang Jiang

职称

Title

教授(博士生导师

Professor (Doctoral advisor)

学位

Degree

博士

Ph.D.

专业

Profession

生物化学与分子生物学

Biochemistry and Molecular Biology

电话/Tel

0591-22867273

邮箱/Email

jianglg@fzu.edu.cn


https://cms.fzu.edu.cn/_vsl/9222DB316A439B81A357EC3BD2AB215C/F312E64B/5C8?e=.gif 教育经历/Education


2005.09 - 2010.07中国科学院福建物质结构研究所,博士/Fujian Institute of Material Structure, Chinese Academy of Sciences,Ph.D.

(导师/Supervisor:黄明东 研究员/Prof. Mingdong Huang)

2001.09 - 2005.07:贵州大学,学士/Guizhou University, Bachelor


https://cms.fzu.edu.cn/_vsl/9222DB316A439B81A357EC3BD2AB215C/F312E64B/5C8?e=.gif工作经历/Career


2016.02 – 至  今福州大学化学学院/College of Chemistry, Fuzhou University

2021.03 – 2023.02:国家自然科学基金委员会/National Natural Science Foundation of China,流动编制业务主管

2018.10 2019.10:美国哈佛医学院,访问学者/Harvard Medical School,Visiting Scholar

(合作导师/Supervisor: Prof. Robert C. Flaumenhaft, MD, Ph.D.

2014.07 2014.10:丹麦奥胡斯大学,访问学者/Aarhus University, Visiting Scholar

(合作导师/Supervisor: Prof. Peter A. Andreasen, Ph.D. )

2010.07 2016.01:中国科学院福建物质结构研究所,助理研究员/Fujian Institute of Material Structure, Chinese Academy of Sciences,Research Associate


https://cms.fzu.edu.cn/_vsl/9222DB316A439B81A357EC3BD2AB215C/F312E64B/5C8?e=.gif教学简介/Teaching


《生物化学》/Biochemistry

《制药工程专业英语》/Professional English for Pharmaceutical Engineering

《综合化学实验》/Comprehensive Chemical Experiments

《制药工程创新创业实践》/Pharmaceutical Engineering Innovation and Entrepreneurship Practice


https://cms.fzu.edu.cn/_vsl/9222DB316A439B81A357EC3BD2AB215C/F312E64B/5C8?e=.gif科研简介/Scientific Research


通过生物化学、分子生物学、生物物理学等手段,围绕以下研究方向开展工作:

1)内皮细胞稳态的调控(PECAM-1Ang/Tie

Regulation of endothelial cell homeostasis (PECAM-1Ang/Tie)

2)凝血系统中水解酶的结构和功能研究(凝血因子VIIXI、血浆激肽酶)

Study on the structure and function of serine proteases in the coagulation system (coagulation factors VII and XI, Plasma Kalinin)

3)纤溶系统在肿瘤侵袭和转移中的调控研究(尿激酶-尿激酶受体)

The regulation of fibrinolytic system in tumor invasion and metastasis (uPA-uPAR)

4)利用枯草芽孢杆菌系统作为模式生物研究细胞分化的调控机制

Study the regulation mechanism of cell differentiation in the Bacillus subtilis system.

(5)体外诊断(IVD)原材料及诊断试剂盒的研发

Development of in vitro diagnostic (IVD) materials and diagnostic kits

作为项目负责人承担多项国家自然科学基金,福建省自然科学基金及技术转化项目等课题,已发表SCI论文70余篇,并以第一作者或通讯作者发表SCI论文30余篇,参编1部专著,获授权专利9项。

研究生招生专业:生物化工、药理学、药物分析、制药工程等。欢迎有志从事科研工作的硕士生/博士生报考我们课题组。


https://cms.fzu.edu.cn/_vsl/9222DB316A439B81A357EC3BD2AB215C/F312E64B/5C8?e=.gif社会兼职/Academic Service


福建省生物工程学会,理事/Fujian Biological Engineering Society


https://cms.fzu.edu.cn/_vsl/9222DB316A439B81A357EC3BD2AB215C/F312E64B/5C8?e=.gif科研及教改项目/Grants  


1.国家自然科学基金面上项目(32370990),2024-2027,项目负责人

National Natural Science Foundation of China (32370990), 2024-2027, PI

2.国家自然科学基金面上项目(82070142),2021-2024,项目负责人

National Natural Science Foundation of China (82070142), 2021-2024, PI

3.国家自然科学基金青年基金(31400637),2015-2017,项目负责人

National Natural Science Foundation of China (31400637), 2015-2017, PI

4.国家重点研发计划项目(2023YFE0118400),2023-2026,研究骨干

National Key R&D Program (2023YFE0118400), 2023-2026, Participant.

5.国家重点研发计划项目(2017YFE0103200),2018-2021,研究骨干

National Key R&D Program (2017YFE0103200), 2018-2021, Participant.

6.福建省高校产学研联合创新项目(2023Y4016),2023-2026,项目负责人

Project of University-Industry-Research Joint Innovation of Fujian Province (2023Y4016),2023-2026,PI

7.福建省科技创新重点项目(2021G02004),2022-2023,项目负责人

Key Project of Science and Technology Innovation of Fujian Province, 2022-2023,PI

8.福建省自然科学基金面上项目(2018J01729),2018-2021,项目负责人

Natural Science Foundation of Fujian Province (2018J01729), 2018-2021, PI

9.福建省自然科学基金青年创新项目2012J05071),2012-2015,项目负责人

Natural Science Foundation of Fujian Province (2012J05071), 2012-2014, PI

10.横向项目,2020-2023,项目负责人

Industry project, 2020-2023, PI

11.横向项目,2023-2024,项目负责人

Industry project, 2023-2024, PI

12.福建省双一流课程建设经费,2020-2025,课程负责人


https://cms.fzu.edu.cn/_vsl/9222DB316A439B81A357EC3BD2AB215C/F312E64B/5C8?e=.gif代表性论文/First or corresponding author publications

(*: Equal contributions; #: co-corresponding authors)


34.Zhao, H.; Huang, M.*; Jiang, L*. Potential Roles and Future Perspectives of Chitinase 3-like 1 in Macrophage Polarization and the Development of Diseases. Int. J. Mol. Sci. 2023, 24, 16149.

33.Zhou Y, Yu S, Chen D, Li H, Xu P, Yuan C, Jiang L*, Huang M*. Nafamostat Mesylate in Combination with the Mouse Amino-Terminal Fragment of Urokinase-Human Serum Albumin Improves the Treatment Outcome of Triple-Negative Breast Cancer Therapy. Mol Pharm. 2023 Feb 6;20(2):905-917.

32.Zhang, X; Sun, G; Yuan, C; Jiang, L*; Huang, M*. Structural Studies of Bypass of Forespore Protein C from Bacillus Subtilis to Reveal Its Inhibitory Molecular Mechanism for SpoIVB. Catalysts 2022, 12, 1530.

31. Lin Y, Chen J, Mai Y, Chen L, Chen Z, Wang G, Deng L, Xu P, Yuan C, Jiang L*, Huang M*. Double-Grafted PET Fiber Material to Remove Airborne Bacteria with High Efficiency. ACS Appl Mater Interfaces. 2022 Oct 19;14(41):47003-47013.

30. Zhou Y, Wu J, Xue G, Li J, Jiang L*, Huang M*. Structural study of the uPA-nafamostat complex reveals a covalent inhibitory mechanism of nafamostat. Biophys J. 2022 Aug 29:S0006-3495(22)00694-4.

29.Wang R, Yang M, Jiang L*, Huang M*. Role of Angiopoietin-Tie axis in vascular and lymphatic systems and therapeutic interventions. Pharmacol Res. 2022 Aug;182:106331.

28. Sun G, Sui Y, Zhou Y, Ya J, Yuan C, Jiang L*, Huang M*. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat. J Virol. 2021;95(19):e0086121.

27. 王蕊,黄美娟,许燕艳,袁彩,黄明东*江龙光*Ang-Tie轴在血管和淋巴系统相关疾病中作用的研究进展,生物工程学报202137(8): 2633-2644.

26. Ma H#, Li R#, Jiang L#, Qiao S, Chen XX, Wang A, Zhang G. Structural comparison of CD163 SRCR5 from different species sheds some light on its involvement in porcine reproductive and respiratory syndrome virus-2 infection in vitro. Vet Res. 2021;52(1):97.

25 Sun G, Yang M, Jiang L*, Huang M*. Regulation of pro-σK activation: a key checkpoint in Bacillus subtilis sporulation. Environ Microbiol. 2021;23(5):2366-2373.

24 Jiang L, Yuan C, Huang M. A general strategy to inhibit serine protease by targeting its autolysis loop. FASEB J. 2021;35(2):e21259.

23. Yuan C, Guo Z, Yu S, Jiang L*, Huang M*. Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners. Drug Discov Today. 2021;26(4):1076-1085.

22. Huang M, Li L, Shen J, Wang Y, Wang R, Yuan C, Huang M*, Jiang L*. Plasma levels of the active form of suPAR are associated with COVID-19 severity. Crit Care. 2020;24(1):704.

21. Zhou Y, Chen D, Xue G, Yu S, Yuan C, Huang M*, Jiang L*, Improved therapeutic efficacy of quercetin-loaded polymeric nanoparticles on triple-negative breast cancer by inhibiting uPA, RSC Adv., 2020,10, 34517-34526.

20. G Xue, X Xie, Y Zhou, C Yuan, M Huang*, Jiang L*. Insight to the residue in P2 position prevents the peptide inhibitor from being hydrolyzed by serine proteases. Biosci Biotechnol Biochem. 2020;84(6):1153-1159.

19. Xie X, Guo N, Xue, Xie D, Yuan C, Harrison J, Li J, L. Jiang L*, Huang M*. Solution structure of SpolVB reveals mechanism of PDZ domain-regulated protease activity. Frontiers in Microbiology, 2019;10,1232.

18. Jiang J, Xie X, Li J, Persson E, Huang M. Crystal structure, epitope and functional impact of an antibody against a super-active FVIIa provide insights into allosteric mechanism. Research and Practice in Thrombosis & Haemostasis, 2019; 3(3);412-419.

17. Jiang L, Zhang X, Zhou Y, Chen Y, Luo Z,  Li J, Yuan C, Huang M. Halogen bonding for the design of inhibitors by targeting the S1 pocket of serine proteases. RSC Advances, 2018;8, 28189.

16. Jiang L, Oldenburg E, Kromann-Hansen T, Xu P, Jensen JK, Andreasen PA, Huang M. Cleavage of peptidic inhibitors by target protease is caused by peptide conformational transition. Biochim Biophys Acta. 2018;1862(9):2017-2023.

15. Sun YG#, Li R#, Jiang L#, Qiao S, Zhi Y, Chen XX, Xie S, Wu J, Li X, Deng R, Zhang G. Characterization of the interaction between recombinant porcine aminopeptidase N and spike glycoprotein of porcine epidemic diarrhea virus. Int J Biol Macromol. 2018; 117:704-712.

14. Xie X, Xue G, Jiang L*, Huang M*. Ligand Induced Conformational Transitions of Tissue Factor Ω loop, Chinese J. Struct. Chem. 2018;37(6), 961-968.

13. Xu M, Chen Y, Xu P, Andreasen PA, Jiang L*, Li J*, Huang M*. Crystal structure of plasma kallikrein reveals the unusual flexibility of the S1 pocket triggered by Glu217. FEBS Lett. 2018;592(15):2658-2667.

12. Xu M, Xu P, Zhou X, Andreasen PA, Jiang L*, Huang M*. Crystal structures of the serine protease domain of murine plasma kallikrein, Chinese J. Struct. Chem. 2017, 36(2), 961-968.

11. Xue G, Gong L, Yuan C, Xu M, Wang X, Jiang L*, Huang M*. A structural mechanism of flavonoids in inhibiting serine proteases. Food Funct. 2017;8(7):2437-2443.

10. Ma H, Qiao S, Huang M, Jiang L*, Li R*, Zhang G*. Crystal Structure of a CD163 Scavenger Receptor Cysteine-rich Domain Produced in Pichia Pastoris, Chinese J. Struct. Chem. 2017, 36(9), 961-968.

9. Ma H#, Jiang L#, Qiao S, Zhi Y, Chen XX, Yang Y, Huang X, Huang M, Li R, Zhang GP. Crystal Structure of the Fifth Scavenger Receptor Cysteine-Rich Domain (SRCR5) from Porcine CD163 Reveals an Important Residue Involved in Porcine Reproductive and Respiratory Syndrome Virus Infection. J Virol. 2017;91(3): e01897-16.

8. Jiang L, Lin L, Li R, Yuan C, Xu M, Huang JH, Huang M. Dimer conformation of soluble PECAM-1, an endothelial marker. Int J Biochem Cell Biol. 2016;77 (Pt A):102-108.

7. Jiang L, Andersen LM, Andreasen PA, Chen L, Huang M. Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate. Biochim Biophys Acta-General subjects. 2016; 1860 (3):599-606.

6. Jiang L, Zhao B, Xu P, Sørensen HP, Jensen JK, Christensen A, Hosseini M, Nielsen NC, Jensen KJ, Andreasen PA, Huang M. Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues. Int J Biochem Cell Biol. 2015; 62:88-92.

5. Jiang L, Botkjaer KA, Andersen LM, Yuan C, Andreasen PA, Huang M. Rezymogenation of active urokinase induced by an inhibitory antibody. Biochem J. 2013 Jan 1; 449 (1): 161-6.

4. Jiang L*, Svane AS*, Sørensen HP, Jensen JK, Hosseini M, Chen Z, Weydert C, Nielsen JT, Christensen A, Yuan C, Jensen KJ, Nielsen NC, Malmendal A, Huang M, Andreasen PA. The Binding Mechanism of a Peptidic Cyclic Serine Protease Inhibitor. J Mol Biol. 2011;412(2), 235-50.

3. Jiang L, Yuan, C, Chen, H, Wang, Y, Zhao, B, Zhang, X, and Huang, M, Preparation and structure of a new coagulation factor XI catalytic domain for drug discovery. Chinese J. Struct. Chem. 2011;30 (7), 1021-59.

2. Jiang L, Zhao G, Bian C, Yuan C, Huang Z, Huang M. Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic Acid and 4-(Aminomethyl-phenyl)-methanol. Chinese J. Struct. Chem. 2009; 28(2), pp. 253-259.

1. Jiang, L, Yu H, Yuan C, Wang J, Chen L, Edward J. Meehan, Huang Z, Huang M. The Crystal Structures of 2-Aminobenzothiazole-based Inhibitors in Complexes with Urokinase-type Plasminogen Activator. Chinese J. Struct. Chem. 2009;28(11):1427-1432.


https://cms.fzu.edu.cn/_vsl/9222DB316A439B81A357EC3BD2AB215C/F312E64B/5C8?e=.gif获奖情况  


2020年度“鸿耀奖教奖”;2021年“厦航奖教奖”


https://cms.fzu.edu.cn/_vsl/9222DB316A439B81A357EC3BD2AB215C/F312E64B/5C8?e=.gif其他


专著

1. Iqbal Z, Jiang L, Chen Z, Yuan C, Li R, Zheng K, Zhou X, Chen J, Hu P, Huang M (2017) Tumor specific imaging and photodynamic therapy targeting on urokinase receptor, chapter 13, page 259-274. In “Imaging in Photodynamic Therapy” Edited by Michael R. Hamblin and Yingying Huang, Taylor & Francis Group, 6000 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487-2742 CRC Press 2017



上一篇:郑允权
下一篇:陈兆委